RECURRENT FOLLICULAR LYMPHOMA
Clinical trials for RECURRENT FOLLICULAR LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT FOLLICULAR LYMPHOMA trials appear
Sign up with your email to follow new studies for RECURRENT FOLLICULAR LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Targeted drug combo aims to tackle Hard-to-Treat lymphoma
Disease control Recruiting nowThis phase II trial tests whether combining brentuximab vedotin (a targeted antibody that delivers a toxin to cancer cells) with bendamustine (a chemotherapy drug) can shrink tumors in people with follicular lymphoma that has come back or not responded to prior treatment. The stu…
Matched conditions: RECURRENT FOLLICULAR LYMPHOMA
Phase: PHASE2 • Sponsor: University of California, Davis • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New drug duo aims to outsmart Hard-to-Treat lymphoma
Disease control Recruiting nowThis phase 2 trial is testing whether combining two drugs, pirtobrutinib and mosunetuzumab, can better treat follicular lymphoma that has relapsed or is refractory. Pirtobrutinib blocks a protein that helps cancer cells grow, while mosunetuzumab helps the body's immune T cells at…
Matched conditions: RECURRENT FOLLICULAR LYMPHOMA
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Engineered immune cells take on Hard-to-Treat blood cancers
Disease control Recruiting nowThis early-phase trial is testing a new type of CAR T-cell therapy called MC10029 for people with B-cell blood cancers that have returned or not responded to treatment. The therapy involves taking a patient's own immune cells, modifying them in the lab to target a protein called …
Matched conditions: RECURRENT FOLLICULAR LYMPHOMA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New pill Q702 aims to outsmart blood cancers in early trial
Disease control Recruiting nowThis early-stage trial is testing a new drug called Q702 in people with various blood cancers and related disorders that have not responded to standard treatments. Q702 is designed to help the immune system attack cancer cells and help the bone marrow make healthy blood cells. Th…
Matched conditions: RECURRENT FOLLICULAR LYMPHOMA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC